Pharmaceutical Market Europe • April 2023 • 34-36
APPOINTMENTS
LEO Pharma
Jacob Pontoppidan Thyssen
LEO Pharma has appointed Jacob Pontoppidan Thyssen as executive vice president and chief scientific officer, following the company’s decision to split its research and development organisation into two distinct functions. Thyssen will remain affiliated with the University of Copenhagen, where he has served as a professor for more than 20 years, as well as with Bispebjerg Hospital, the largest dermatology department in Denmark. He has been a research fellow at Harvard Medical School, the University of California and University Spital Zürich, where his research focused on atopic dermatitis and the complexity of the skin barrier. Thyssen is also a member of several societies and working groups, including the International Eczema Council, where he serves as a director, the European Task Force of Atopic Dermatitis, the European Society of Contact Dermatitis and the European Dermato-Epidemiology Network.
Datapharm
Rich Cooper
Datapharm has appointed Rich Cooper as chief executive officer. Cooper has over 25 years’ experience within the pharmaceutical and healthcare industry, and joins the company from his most recent position of chief commercial officer at Cambridge Cognition. He has also held various leadership roles at AstraZeneca, AbbVie, Otsuka and IQVIA, and worked at a senior level within an NHS Trust.
Sobi
Tony Hoos
Sobi has appointed Tony Hoos as head of research development and medical affairs, and chief medical officer. Hoos brings more than three decades of experience from the global pharmaceutical industry to the role, including a variety of positions at Amgen, GSK, Genomics, Aventis and Valo Health. He was also most recently a member of the board of non-profit organisation Patient Focused Medicine Development.
Hansa Biopharma
Matthew Shaulis
Hansa Biopharma has appointed Matthew Shaulis as chief commercial officer and president of its US affiliate, Hansa Biopharma. Shaulis joins the company with over 20 years’ experience in the pharmaceutical industry, having most recently held several senior executive roles at Pfizer. Prior to this, he held various roles of increasing responsibility at Teva, Cephalon, Johnson & Johnson and Schering-Plough.
IRLAB Therapeutics AB
Gunnar Olsson
IRLAB Therapeutics AB has appointed Gunnar Olsson as interim chief executive officer. Olsson, who has been chairman of the company’s board since 2020, has more than 30 years of experience in leading positions in the life sciences industry, such as VP and head of cardiovascular and gastrointestinal therapy areas in global R&D at AstraZeneca. He has also served on the board of the European Society of Cardiology.
Novo Nordisk
Dave Moore
Novo Nordisk has appointed Dave Moore as executive vice president, corporate development. Moore joined the company in September last year as senior vice president, corporate development. He was also senior vice president, commercial operations at Novo in the US from 2017 to 2019, and has held various leadership roles in the industry, such as with Roivant Sciences and Cempra Pharmaceuticals.
Novo Nordisk
Tania Sabroe
Novo Nordisk has appointed Tania Sabroe as executive vice president, global people and organisation. Sabroe originally joined the company in August 2007 and most served as senior vice president, global people and organisation. Prior to this, she held a variety of positions within the company of increasing importance and complexity in the field of people and organisation, sustainability and communication.
Biogen
Chuck Triano
Biogen has appointed Chuck Triano as senior vice president, head of investor relations. Triano brings over 35 years of financial experience to the role, having held executive positions across biotechnology and pharmaceutical companies over the last two decades. He was most recently chief financial officer at Xalud Therapeutics, prior to which he was senior vice president of investor Relations at Pfizer.
Alnylam Pharmaceuticals
Peter Kellogg
Alnylam Pharmaceuticals has appointed Peter Kellogg to its board of directors. Kellogg joins the company having most recently served as executive vice president, chief corporate strategy officer at Celgene. Prior to this, Kellogg held the position of chief financial officer at Merck & Co, Biogen and Frito Lay International. He also currently serves as a member of Idorsia’s board of directors.
ABPI
Susan Rienow
The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow as president. Rienow became vice president in September 2022 and has been serving as acting president following the recent departure of Pinder Sahota, but will now take on the role fully in May this year. Rienow is the UK country president of Pfizer, where she leads the company's medicines and vaccines portfolio. Prior to this, Rienow led Pfizer UK’s vaccines business unit during the COVID-19 pandemic and previously led Pfizer’s UK Hospital business unit and Essential Health division. Rienow has been at Pfizer for over two decades, with experience across multiple global markets including in the US, Asia and Europe. In her new role at the ABPI, she will lead the organisation's board to deliver on its mission to make the UK a global leader in the research, development and use of new medicines and vaccines.
Sonata Therapeutics
Francesco Marincola
Sonata Therapeutics has appointed Francesco Marincola as chief scientific officer. Marincola was most recently senior vice president and global head of cell therapy research at Kite Pharma. Previous industry roles include president and chief scientific officer at Refuge Biotechnologies, distinguished research fellow in immune oncology at AbbVie, and chief research officer at Sidra Medical and Research Centre.
Beam Therapeutics
Gopi Shanker
Beam Therapeutics has appointed Gopi Shanker as chief scientific officer. Shanker, who has extensive drug development experience, joins from Tevard Biosciences, where he served as chief scientific officer. Prior to Tevard, Shanker spent eight years in a variety of roles at the Novartis Institutes for Biomedical Research, most recently as head of neuroscience. He has also led several drug discovery programmes at Amgen and Regeneron.
SwedenBIO
Jessica Martinsson
SwedenBIO has appointed Jessica Martinsson as director general. Martinsson brings extensive industry experience to her new role, having co-founded and been both chief operating officer and chief executive officer at Sprint Bioscience. She also has experience working as a research chemist at Pharmacia & Upjohn, chemistry team lead at Biovitrum, and as board member of Lipigon Pharmaceuticals AB.
Immunovia AB
Karl Stone
Immunovia AB has appointed Karl Stone as chief operating officer. Stone joins the company with over 25 years of technical work experience, from industrial bioprocessing to IVD. He was an original member and the first operations director of Oxford Gene Technology, and was head of operations at the Medicines Discovery Catapult, Lighthouse Lab – one of the UK´s network of COVID-19 testing labs.
iOmx Therapeutics
Christine Rothe
iOmx Therapeutics AG has appointed Christine Rothe as chief development officer. Rothe joins the company with over 25 years of biopharma industry experience in research and drug discovery, having most recently served as vice president, early-stage project leadership and data science at Pieris Pharmaceuticals. Prior to this, she was vice president, discovery and alliance management, also at Pieris.
BCB Medical
Marcus Kaber
BCB Medical has appointed Marcus Kaber as chief executive officer. Kaber brings more than 20 years of international experience in the IT industry to his new role, having worked with companies including Netop Business Solutions and Nordic AB. He joins the company from password management and authentication solutions company Specops Software, where he served as CEO for over a decade.
ICER
Linda Goler Blount
The Institute for Clinical and Economic Review (ICER) has appointed Linda Goler Blount to its governance board. Blount is president of the Black Women’s Health Imperative and has previously edited IndexUS, the first research on Black women’s health based on healthy Black women. Her career also includes tenures at CDC, the Coca-Cola Company and consulting with health ministries across multiple countries.
Alligator Bioscience AB
Laura von Schantz
Alligator Bioscience AB has appointed Laura von Schantz as chief technology officer. Schantz originally joined the company in 2014 and was most recently vice president, discovery, a position she has held since January 2021 and in which she played a key role in securing Alligator's research agreements. Prior to that, Schantz was director, antibody engineering, where she was responsible for Alligator's technology platform.
Inizio
Stefanie Christmas
Inizio has appointed Stefanie Christmas as global head of diversity, equity and inclusion (DE&I). Christmas joins the company’s executive team from healthcare industry management consulting firm Vynamic, an Inizio advisory company, where she founded its DE&I efforts in 2016. During her time there, she also co-developed Vynamic’s DE&I consulting service.
Wunderman Thompson Health
Renata Maia
Wunderman Thompson Health, part of WPP Group, has appointed Renata Maia as global chief creative officer. The move marks Maia's return to WPP, where she spent much of her career, at agencies including VMLY&R and Grey. She also spent nearly ten years at then Y&R as regional creative director. Her most recent role was executive VP, group creative director at AREA 23.
The Considered
Bam Zahraie
The Considered has appointed Bam Zahraie as chief experience officer. Zahraie joins the agency from his most recent role as global innovation lead and associate managing director at Havas Health & You (HH&Y). He previously held the role of senior vice president of innovation at Havas Health Plus for two years. In addition to that, he has held a variety of leadership roles at HH&Y.
Envision Pharma Group
James Streeter
Envision Pharma Group has appointed James Streeter as president of technology, chief technology officer. Street joins Envision from Oracle Health Sciences, where he was global prior president, after joining the company in 2014 as senior director, eClinical strategy and innovation. He previously held executive director roles at Pharmaceutical Product Development.
OPEN Health
Laura Brambilla
OPEN Health has appointed Laura Brambilla as chief financial officer. Brambilla has extensive leadership experience within high-growth technology, data and professional services companies. She has been CFO at Octo Telematics Group, Aecom and Alcatel-Lucent, as well as chairman of the Metro line 4 in Milan. She is also a fellow of the council for US and Italy, known as Consiusa.
CMI Media Group
Matt Durham
CMI Media Group has appointed Matt Durham as director, global media. Durham joins the company after spending over a decade in international pharmaceutical and healthcare media planning, as well as strategy. He was most recently senior media strategist at McCann Health. Prior to this, he was director of business development at ONCOassist and has held roles at QxMD and Four Health Media.
Team ITG
Gerhard Arnhofer
Team ITG has appointed Gerhard Arnhofer as head of customer strategy for its life sciences division. Arnhofer joins the agency with more than two decades of experience in the biopharma industry, most recently serving as senior vice president of customer strategy at BioNTech SE. He has also held a variety of senior positions at Merck & Co and Bayer AG.
Lumanity
Ed Saltzman
Lumanity has appointed Ed Saltzman as senior strategic advisor. Saltzman founded Defined Health in 1993 and, following its sale to Cello Health (now Lumanity) in 2017, served as executive chairman of the firm’s biotech business unit. He currently serves on the board at Nurix Therapeutics and as a venture advisor to the Israel Biotech Fund and Hibiscus Capital Management.
Wave Healthcare Communications
Gareth Tucker
Wave Healthcare Communications has appointed Gareth Tucker as commercial director. Tucker brings more than two decades of experience in medical communications to the company, having most recently served as chief executive officer of Obsidian Healthcare Group. Previously, Tucker was managing director at Elements Communications for over four years as group strategy director.
Page & Page and Partners
Donia A
Page & Page and Partners has appointed Donia A as senior account director. She joins the agency with ten years of experience working in roles spanning biochemistry, medical education, brand strategy and HCP and patient engagement. She was most recently account director at Axiom. Prior to this, she was senior account manager at Lucid and healthcare account manager at Kiosk HQ.
IGNIFI
Lucy Rimmer
IGNIFI has appointed Lucy Rimmer as senior digital designer. The appointment marks Rimmer's second promotion. She originally joined the agency seven years ago as a junior designer, before taking on the role of designer. During her time here, Rimmer has worked with all of IGNIFI’s life sciences client brands across a multitude of therapy areas, developing digital design solutions for a wide variety of channels and formats.
Bedrock Healthcare Communications
Lydia Awosika
Bedrock Healthcare Communications has appointed Lydia Awosika as senior account executive. She joins the agency from AbbVie, where she has been serving as medical operations advisor since April 2021. In her new role at Bedrock, Awosika will be working with client services to support the delivery of the agency’s medical communication programmes to its global pharmaceutical and biotech clients.